Načítá se...
ACTR-24. THE ESTIMATED LONG-TERM SURVIVAL BENEFIT OF ADDING TTFIELDS TO THE STANDARD OF CARE FOR GLIOBLASTOMA PATIENTS
BACKGROUND: Glioblastoma (GBM) is the most aggressive form of primary brain cancer. The EF-14 trial for GBM patients reported a 5-year survival rate of 12.8%, the first report from a large randomized controlled trial of 5-year survival greater than 10%. The increased survival compared to previous st...
Uloženo v:
| Vydáno v: | Neuro Oncol |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Oxford University Press
2017
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5692846/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.019 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|